Depletion of B220⁺NK1.1⁺ cells enhances the rejection of established melanoma by tumor-specific CD4⁺ T cells

Kyle A WilsonProgram in Molecular Microbiology and Immunology; University of Maryland School of Medicine; Baltimore, MDUSA;Department of Pathology; University of Maryland School of Medicine; Baltimore, MDUSA

Stephen R GodingDepartment of Pathology; University of Maryland School of Medicine; Baltimore, MDUSA

Harold R NeelyProgram in Molecular Microbiology and Immunology; University of Maryland School of Medicine; Baltimore, MDUSA;Department of Microbiology and Immunology; University of Maryland School of Medicine; Baltimore, MDUSA

Kristina M HarrisImmune Tolerance Network; Bethesda, MDUSA

Paul Andrew AntonyProgram in Molecular Microbiology and Immunology; University of Maryland School of Medicine; Baltimore, MDUSA;Department of Pathology; University of Maryland School of Medicine; Baltimore, MDUSA;Department of Microbiology and Immunology; University of Maryland School of Medicine; Baltimore, MDUSA;Tumor Immunology and Immunotherapy Program; University of Maryland Cancer Center; Baltimore, MDUSACorrespondence[email protected]

Depletion of B220⁺NK1.1⁺ cells enhances the rejection of established melanoma by tumor-specific CD4⁺ T cells

2015ONCOIMM0036R-f07-z-bw.pdf

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells

2015ONCOIMM0036R-f07-z-bw.pdf

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Depletion of B220⁺NK1.1⁺ cells enhances the rejection of established melanoma by tumor-specific CD4⁺ T cells